钟士杰,邓 堂,林开文,廖 勇,魏胜超,李 奇,徐双琴,云宏芳,金桂云.缺氧性肺动脉高压的治疗进展[J].,2021,(18):3596-3600 |
缺氧性肺动脉高压的治疗进展 |
Progress in Treatment of Hypoxic Pulmonary Hypertension |
投稿时间:2021-01-03 修订日期:2021-01-26 |
DOI:10.13241/j.cnki.pmb.2021.18.043 |
中文关键词: 缺氧性肺动脉高压 HPH 治疗 机制 |
英文关键词: Hypoxic pulmonary hypertension HPH Treatment Mechanism |
基金项目:国家自然科学基金项目(31560267) |
|
摘要点击次数: 671 |
全文下载次数: 593 |
中文摘要: |
摘要:缺氧性肺动脉高压(HPH)是指由于长期缺氧导致血管内皮细胞损伤,血管活性因子水平失调,以血管收缩及血管重塑为主要病理表现的一类肺动脉高压症(PAH),HPH发病率高,死亡率高,除了肺移植,目前尚无根治办法,对于HPH的治疗一直是研究热点,本文将结合近年国内外最新研究从基因靶向、离子通道、线粒体、NO相关药物、西药、中药领域对HPH的治疗做一概述。 |
英文摘要: |
ABSTRACT: Hypoxic pulmonary hypertension (HPH) refers to a type of pulmonary arterial hypertension (PAH) with vasoconstriction and vascular remodeling as the main pathological manifestations of vascular endothelial cell damage caused by long-term hypoxia, the incidence of HPH High mortality rate. Except for lung transplantation, there is currently no cure. The treatment of HPH has always been a research hotspot. This article will combine the latest research at home and abroad in recent years from gene targeting, ion channels, mitochondria, NO-related drugs, western medicine, and traditional Chinese medicine. The field gives an overview of the treatment of HPH. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |